Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure

The American Journal of Cardiology
Linnea M BaudhuinAllan S Jaffe

Abstract

The response to beta blockers in patients with heart failure could be associated with the genotype of drug-metabolizing enzymes and/or drug targets. The purpose of the present study was to determine whether specific genetic polymorphisms in ADRB1 (encoding the beta1-adrenergic receptor), CYP2D6, and UGT1A1 correlated with dose of, or response to, metoprolol or carvedilol treatment in patients with heart failure. A cohort of patients with heart failure (n = 93), characterized as responders or nonresponders to metoprolol (n = 19) or carvedilol (n = 74) therapy, was retrospectively identified. Individual genotyping was performed for a panel of polymorphisms in the ADRB1, CYP2D6, and UGT1A1 genes. Univariate and multivariate analyses were performed to compare the genotype to the metoprolol or carvedilol response status and dose. A nonresponse was identified in 10 of 19 patients taking metoprolol and 32 of 74 patients taking carvedilol. None of the polymorphisms in ADRB1, CYP2D6, and UGT1A1 were associated with a response or nonresponse. However, a significant relation between the carvedilol (but not metoprolol) dose and the ADRB1 and CYP2D6 genotype was observed. Patients homozygous for the ADRB1 389Gly variant or who were CYP2D6 p...Continue Reading

References

Dec 1, 1985·British Journal of Clinical Pharmacology·J C McGourtyH F Woods
Dec 16, 1982·The New England Journal of Medicine·M S LennardH F Woods
Aug 13, 2002·Pharmacogenetics·Thomas RauThomas Eschenhagen
Jan 28, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Akiko OhnoJun-ichi Sawada
Aug 5, 2005·Biological & Pharmaceutical Bulletin·Mutsuko HondaYukiya Hashimoto
Feb 16, 2006·Journal of Clinical Pharmacy and Therapeutics·R Ismail, L K Teh
Sep 17, 2008·Pharmacogenetics and Genomics·Daniel KurnikC Michael Stein
Oct 7, 2008·Journal of Clinical Pharmacy and Therapeutics·S K JinJ Roh
Nov 28, 2008·Clinical Pharmacology and Therapeutics·T RauT Eschenhagen

❮ Previous
Next ❯

Citations

Dec 3, 2011·Current Heart Failure Reports·Jasmine A Talameh, David E Lanfear
Apr 18, 2013·Molecular Diagnosis & Therapy·Fabiana Filigheddu
Jan 11, 2012·Nature Reviews. Cardiology·W Robb MacLellanAldons J Lusis
Jun 2, 2011·Future Cardiology·Nicholas B Norgard, Gina M Prescott
May 24, 2011·Pharmacogenomics·Daniel SehrtJürgen Brockmöller
May 25, 2012·Expert Opinion on Drug Metabolism & Toxicology·Sze Wa ChanBrian Tomlinson
Apr 3, 2012·Journal of Cardiac Failure·Jasmine A TalamehJ Herbert Patterson
Aug 10, 2013·The Journal of Pharmacy and Pharmacology·Daniel Valente NevesEvandro José Cesarino
Nov 5, 2016·Pharmacogenomics·Fannie MottetSimon de Denus
Jan 26, 2017·Pharmaceutical Research·Liang LiDanxin Wang
Apr 8, 2017·Mayo Clinic Proceedings·John R GiudicessiMichael J Ackerman
Jan 16, 2016·The Journal of International Medical Research·Mengqi GuoXiaoping Ji
Apr 1, 2015·The Journal of International Medical Research·Dingchang WuJiasen Xu
Jun 12, 2018·Expert Review of Precision Medicine and Drug Development·Michael T EadonArlene B Chapman
Feb 25, 2020·British Journal of Clinical Pharmacology·Maxime MelocheSimon de Denus
Jul 30, 2020·Expert Opinion on Drug Metabolism & Toxicology·Cameron D Thomas, Julie A Johnson
Feb 10, 2017·Pharmaceutical Research·Jasmine A LuzumJoseph P Kitzmiller
Apr 6, 2011·Current Opinion in Cardiology·Gerald W Dorn
Jun 27, 2020·The Journal of Pediatrics·Sara L Van DriestDan M Roden
May 7, 2021·Nature Reviews. Cardiology·Julio D Duarte, Larisa H Cavallari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.